Evidence map›Paper›PMID 34164370›Full record

SynthesisFrontiers in public health2021

SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Nanjing Shi, Yetan Shi, Jingsi Xu, Yuexiu Si, Tong Yang, Mengting Zhang, Derry Minyao Ng, Xiangyuan Li, Fei Xie

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nanjing ShiDepartment of Endocrinology, Affiliated Hangzhou First People' Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yetan ShiThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Jingsi XuThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Yuexiu SiSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Tong YangDepartment of Tumor High Intensity Focused Ultrasound Therapy, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
Mengting ZhangThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Derry Minyao NgMedical College of Ningbo University, Ningbo, China.
Xiangyuan LiThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Fei XieDepartment of Endocrinology, Ningbo Yinzhou No. 2 Hospital, Ningbo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2NeoplasmsSodium-Glucose Transporter 2 InhibitorsHumansHypoglycemic AgentsRandomized Controlled Trials as TopicHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitorsmalignant tumormeta-analysisRCTSGLT-2itype 2 diabetes

Identifiers

PMID34164370
PMCPMC8215266

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.